Prognosis
Pfizer Says Covid Vaccine 91% Effective in Kids Ages 5 to 11
- Data posted in briefing documents ahead of key panel meeting
- Doses one-third of adult size tested in pediatric trials
Photographer: Leon Neal/Getty Images
This article is for subscribers only.
Pfizer Inc. said the Covid-19 shot it developed with BioNTech SE was 90.7% effective against symptomatic cases in children ages 5 to 11, according to a briefing document posted on the Food and Drug Administration’s website.
Outside experts on the FDA’s Vaccines and Related Biological Products Advisory Committee will meet next week to evaluate Pfizer and BioNTech’s application for emergency authorization of their Covid vaccine in young children. If the panel votes to recommend clearance and the FDA agrees, it could pave the way for a Covid vaccine for young kids to be available by the beginning of November.